Human PARP1 Substrates and Regulators of Its Catalytic Activity: an Updated Overview.

Tao Zhu,Ju-Yan Zheng,Ling-Ling Huang,Yan-Hong Wang,Di-Fei Yao,Hai-Bin Dai
DOI: https://doi.org/10.3389/fphar.2023.1137151
IF: 5.6
2023-01-01
Frontiers in Pharmacology
Abstract:Poly (ADP-ribose) polymerase 1 (PARP1) is a key DNA damage sensor that is recruited to damaged sites after DNA strand breaks to initiate DNA repair. This is achieved by catalyzing attachment of ADP-ribose moieties, which are donated from NAD+, on the amino acid residues of itself or other acceptor proteins. PARP inhibitors (PARPi) that inhibit PARP catalytic activity and induce PARP trapping are commonly used for treating BRCA1/2-deficient breast and ovarian cancers through synergistic lethality. Unfortunately, resistance to PARPi frequently occurs. In this review, we present the novel substrates and regulators of the PARP1-catalyzed poly (ADP-ribosyl)ation (PARylatison) that have been identified in the last 3 years. The overall aim is the presentation of protein interactions of potential therapeutic intervention for overcoming the resistance to PARPi.
What problem does this paper attempt to address?